Anticoagulation Management for Antiphospholipid Syndrome

Diagnosis and Classification

The American Heart Association recommends testing for antiphospholipid syndrome (APS) in patients with prior venous thromboembolism, second trimester abortion, rheumatologic disorders, or cryptogenic stroke with history of thrombosis 1
APS is characterized by persistent presence of lupus anticoagulant, anti-cardiolipin, or anti-β2 glycoprotein-I antibodies plus evidence of vascular thrombosis or pregnancy morbidity 1
Triple-positive APS (positive for lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein-I antibodies) represents the highest risk category 2, 3

The American College of Chest Physicians recommends warfarin with target INR 2.0-3.0 as first-line therapy for confirmed APS 1, 4, 5, 6
Warfarin with target INR 2.5 (range 2.0-3.0) provides optimal balance between thrombosis prevention and bleeding risk 6
Rivaroxaban is specifically contraindicated in APS, especially in triple-positive patients, due to excess thrombotic events compared to warfarin 1, 2, 3
Other direct oral anticoagulants (DOACs) should also be avoided until further evidence is available 2, 3
Antiplatelet therapy alone (aspirin) is recommended for patients with isolated antiphospholipid antibody who do not fulfill criteria for APS 1, 4

Triple-positive APS patients require particularly careful monitoring and strict adherence to warfarin therapy 2, 3
Avoid high-intensity warfarin (INR 3.0-4.5) as it does not provide additional benefit over moderate intensity (INR 2.0-3.0) but increases bleeding risk 6, 7
DOACs should not be used in APS patients due to increased thrombotic risk, especially in triple-positive patients 1, 2, 3
When testing for thrombophilic states like APS, testing should be deferred or repeated at least 4-6 weeks after acute thrombosis as protein levels may be altered during the acute phase 8

The American Heart Association recommends warfarin with target INR 2.5 (range 2.0-3.0) as the gold standard for thrombotic APS, regardless of protein C levels or anti-protein C antibody status 9
For venous thrombosis in APS, the American College of Chest Physicians suggests long-term (often indefinite) warfarin with target INR 2.0-3.0 9
Warfarin itself can transiently decrease protein C levels during initiation, creating a theoretical hypercoagulable state, which is why heparin bridging for 5-7 days is recommended when starting warfarin in APS, as stated by the American College of Chest Physicians 10